Potential role of angiotensin-converting enzyme inhibitors vs beta-blockers in preventing anticancer agents-induced cardiotoxicity: A systematic review and meta-analysis

doi:10.4330/wjc.120930

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(24)

(21)

(0)

(334)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. Jun 26, 2026; 18(6): 120930
Published online Jun 26, 2026. doi: 10.4330/wjc.120930

Table 1 Tabulated representation of baseline characteristics of included randomized controlled trials

Ref.	Type of study	Type of malignancy	Anti-cancer agent used	Beta blocker used	ACEI used	Location	Total study population (n)	Beta blocker (n)	ACEI/ARBs (n)	Duration of study
Pituskin et al[17], 2017	Randomized control trial	Breast	Transtuzumab	Bisoprolol	Perindopril	Canada	64	31	33	3 years
Guglin et al[18], 2019	Randomized control trial	Breast cancer	Transtuzumab	Carvedilol	Lisinopril	United States	314	156	158	12 months
Barletta et al[19], 2023	Phase 3 Randomized control trial	Breast cancer	Anthracycline	Bisoprolol	Ramipril	Italy	132	66	66	2 years
Georgakopoulos et al[20], 2010	Randomized control trial	Lymphoma	Anthracycline	Metoprolol	Enalapril	Greece	85	42	43	36 months

ACEI: Angiotensin-converting enzymes inhibitors; ARB: Angiotensin II receptor blockers.

Full Size Table

Citation: Sohail R, Khattak R, Hussain Shah H, Khan Z, Khan A, Chaudhry S, Patel S, Patel R, Patel V, Alam M, Mehdi S, Singh M. Potential role of angiotensin-converting enzyme inhibitors vs beta-blockers in preventing anticancer agents-induced cardiotoxicity: A systematic review and meta-analysis. World J Cardiol 2026; 18(6): 120930
URL: https://www.wjgnet.com/1949-8462/full/v18/i6/120930.htm
DOI: https://dx.doi.org/10.4330/wjc.120930

Sohail R, Khattak R, Hussain Shah H, Khan Z, Khan A, Chaudhry S, Patel S, Patel R, Patel V, Alam M, Mehdi S, Singh M. Potential role of angiotensin-converting enzyme inhibitors vs beta-blockers in preventing anticancer agents-induced cardiotoxicity: A systematic review and meta-analysis. World J Cardiol 2026; 18(6): 120930 [DOI: 10.4330/wjc.120930]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.